NCT02750137

Brief Summary

Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. However, the incidences of adverse reactions seemed to be higher compared to other studies. This lead to a prospective observational study to look at the incidence and severity of skin reactions following routine clinical application of Ametop.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
192

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2014

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

April 17, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 25, 2016

Completed
Last Updated

April 25, 2016

Status Verified

April 1, 2016

Enrollment Period

9 months

First QC Date

April 17, 2016

Last Update Submit

April 22, 2016

Conditions

Keywords

Tetracaine

Outcome Measures

Primary Outcomes (1)

  • Incidence of skin reactions with Ametop

    looking at the incidence of skin reactions with Ametop - normal, simple erythema, raised erythema, itch, pallor

    October 2014 to May 2015

Secondary Outcomes (1)

  • Risk factors associated with incidence of skin reactions

    October 2014 to May 2015

Interventions

Application of Ametop prior to intravenous cannulation

Also known as: Ametop

Eligibility Criteria

Age1 Month - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Paediatric patients presenting for surgery in KK Women's and Children's Hospital

You may qualify if:

  • All paediatric patients presenting for surgery from August 2014 to May 2015 who have had Ametop applied prior to intravenous cannulation.

You may not qualify if:

  • Any patient who did not have Ametop applied or have an intravenous cannula in situ.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Browne J, Awad I, Plant R, McAdoo J, Shorten G. Topical amethocaine (Ametop) is superior to EMLA for intravenous cannulation. Eutectic mixture of local anesthetics. Can J Anaesth. 1999 Nov;46(11):1014-8. doi: 10.1007/BF03013194.

    PMID: 10566919BACKGROUND
  • Arrowsmith J, Campbell C. A comparison of local anaesthetics for venepuncture. Arch Dis Child. 2000 Apr;82(4):309-10. doi: 10.1136/adc.82.4.309.

    PMID: 10735838BACKGROUND

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions

Interventions

Tetracaine

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Intervention Hierarchy (Ancestors)

para-AminobenzoatesAminobenzoatesBenzoatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Angela YJ Tan, MMed

    KK Women's and Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Resident

Study Record Dates

First Submitted

April 17, 2016

First Posted

April 25, 2016

Study Start

August 1, 2014

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

April 25, 2016

Record last verified: 2016-04

Data Sharing

IPD Sharing
Will not share

Data will be protected and not shared.